Javascript must be enabled to continue!
Psychological Disorders in Patients With Resistant Hypertension and the Effect of Psychotherapy Combined With Antidepressant/Anxiolytics
View through CrossRef
Abstract
OBJECTIVE
To explore the clinical characteristics and related influencing factors of psychological disorders in patients with resistant hypertension (RH), and to analyze the therapeutic effect of psychotherapy combined with antidepressant/anxiolytics.
METHODS
A total of 247 patients with RH were consecutively selected from the Cardiovascular Department of Xiangya Hospital, Central South University from May 2021 to August 2023. The general demographic data were collected, and the psychological disorders were evaluated by the generalized anxiety disorder-7 items scale (GAD-7), patient health questionnaire-9 items scale (PHQ-9), and patient health questionnaire-15 items scale (PHQ-15). The patients with RH complicated with psychological disorders were treated with psychotherapy combined with flupentixol melitracen-based drugs for 3 months on the basis of the original antihypertensive scheme. The antihypertensive efficacy, the number of antihypertensive drugs, and the changes in GAD-7, PHQ-9, and PHQ-15 were analyzed.
RESULTS
The detection rates of RH combined with anxiety, depression, and somatization were 41.7%, 38.5%, and 68.8%, respectively, and the total detection rate of mental disorders was 71.3%. Multivariate logistic regression analysis showed that life stress (odds ratio [OR] = 3.842, 95% confidence interval [CI] 1.752–8.427), PHQ-9 score (OR = 1.183, 95% CI 1.085–1.290), and PHQ-15 score (OR = 1.284, 95% CI 1.146–1.440) were independent risk factors for anxiety state, and the long course of disease (OR = 1.693, 95% CI 1.086–2.639), GAD-7 score (OR = 1.181, 95% CI 1.084–1.286), and PHQ-15 score (OR = 1.390, 95% CI 1.231–1.569) were independent risk factors for depression. The GAD-7 score (OR = 1.206, 95% CI 1.036–1.404) and PHQ-9 score (OR = 1.419, 95% CI 1.152–1.748) were independent risk factors for somatic symptoms. Somatic symptom score was significantly positively correlated with GAD-7 (rs = 0.705, P < 0.001) and PHQ-9 (rs = 0.742, P < 0.001), respectively. After treatment, the total effective rate was 94.9%, the blood pressure control rate was 83.5%, and in 51.3% of patients, the number of antihypertensive drugs taken decreased by ≥1. After treatment, the scores of GAD-7, PHQ-9, PHQ-15, and blood pressure were all decreased (all P < 0.001).
CONCLUSIONS
RH patients have a high incidence of psychological disorders, with somatization symptoms as a prominent manifestation. Anxiety, depression, and somatization symptoms interact and influence each other. Psychotherapy combined with antidepressant/anxiolytic therapy can improve the antihypertensive effect, and improve their anxiety, depression, and somatization symptoms in RH patients with mental disorders.
Title: Psychological Disorders in Patients With Resistant Hypertension and the Effect of Psychotherapy Combined With Antidepressant/Anxiolytics
Description:
Abstract
OBJECTIVE
To explore the clinical characteristics and related influencing factors of psychological disorders in patients with resistant hypertension (RH), and to analyze the therapeutic effect of psychotherapy combined with antidepressant/anxiolytics.
METHODS
A total of 247 patients with RH were consecutively selected from the Cardiovascular Department of Xiangya Hospital, Central South University from May 2021 to August 2023.
The general demographic data were collected, and the psychological disorders were evaluated by the generalized anxiety disorder-7 items scale (GAD-7), patient health questionnaire-9 items scale (PHQ-9), and patient health questionnaire-15 items scale (PHQ-15).
The patients with RH complicated with psychological disorders were treated with psychotherapy combined with flupentixol melitracen-based drugs for 3 months on the basis of the original antihypertensive scheme.
The antihypertensive efficacy, the number of antihypertensive drugs, and the changes in GAD-7, PHQ-9, and PHQ-15 were analyzed.
RESULTS
The detection rates of RH combined with anxiety, depression, and somatization were 41.
7%, 38.
5%, and 68.
8%, respectively, and the total detection rate of mental disorders was 71.
3%.
Multivariate logistic regression analysis showed that life stress (odds ratio [OR] = 3.
842, 95% confidence interval [CI] 1.
752–8.
427), PHQ-9 score (OR = 1.
183, 95% CI 1.
085–1.
290), and PHQ-15 score (OR = 1.
284, 95% CI 1.
146–1.
440) were independent risk factors for anxiety state, and the long course of disease (OR = 1.
693, 95% CI 1.
086–2.
639), GAD-7 score (OR = 1.
181, 95% CI 1.
084–1.
286), and PHQ-15 score (OR = 1.
390, 95% CI 1.
231–1.
569) were independent risk factors for depression.
The GAD-7 score (OR = 1.
206, 95% CI 1.
036–1.
404) and PHQ-9 score (OR = 1.
419, 95% CI 1.
152–1.
748) were independent risk factors for somatic symptoms.
Somatic symptom score was significantly positively correlated with GAD-7 (rs = 0.
705, P < 0.
001) and PHQ-9 (rs = 0.
742, P < 0.
001), respectively.
After treatment, the total effective rate was 94.
9%, the blood pressure control rate was 83.
5%, and in 51.
3% of patients, the number of antihypertensive drugs taken decreased by ≥1.
After treatment, the scores of GAD-7, PHQ-9, PHQ-15, and blood pressure were all decreased (all P < 0.
001).
CONCLUSIONS
RH patients have a high incidence of psychological disorders, with somatization symptoms as a prominent manifestation.
Anxiety, depression, and somatization symptoms interact and influence each other.
Psychotherapy combined with antidepressant/anxiolytic therapy can improve the antihypertensive effect, and improve their anxiety, depression, and somatization symptoms in RH patients with mental disorders.
Related Results
Pharmacological Characteristics of Anxiolytics on Acetylcholine-Induced Contractions in Rat Detrusor Smooth Muscle
Pharmacological Characteristics of Anxiolytics on Acetylcholine-Induced Contractions in Rat Detrusor Smooth Muscle
<b><i>Introduction:</i></b> Benzodiazepine anxiolytics are believed to cause urination disorders due to their anticholinergic effects. <b><i>Obj...
Pharmacogenomics and the Concept of Personalized Medicine for the Management of Hypertension
Pharmacogenomics and the Concept of Personalized Medicine for the Management of Hypertension
Hypertension poses a significant global burden due to low adherence to antihypertensive medications. Hypertension treatment aims to bring blood pressure within physiological ranges...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Epidemiology, Etiology, Screening, Psychotherapy of Malignant Tumor Patients with Secondary Depressive Disorder
Epidemiology, Etiology, Screening, Psychotherapy of Malignant Tumor Patients with Secondary Depressive Disorder
The incidence of malignant tumors has been increasing year by year worldwide. Psychological problems
related to cancer development have also received increasing attention from the ...
Adverse Effects of Psychotherapy
Adverse Effects of Psychotherapy
<p><strong>Context and relevance.</strong> Not ignoring possible negative results of psychotherapy, Russian researchers mainly pay attention to clinical side effe...
Amygdala reactivity, antidepressant discontinuation and relapse: a longitudinal, observational study with a randomized component
Amygdala reactivity, antidepressant discontinuation and relapse: a longitudinal, observational study with a randomized component
Importance: Antidepressant discontinuation substantially increases the risk of a depression relapse. The neurobiological mechanisms through which this happens are not known. Amygda...
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
AbstractThe discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor (NMDAR) antagonist (R,S)-ketamine has been a crucial breakthrough in mood disord...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

